Text size Dreamstime Older adults who participated in Moderna‘s Phase 1 trial of its Covid-19 vaccine responded just as well as younger adults, according to data, the biotech company presented Wednesday morning to a key Centers for Disease Control and Prevention Advisory panel. This is important because Covid-19 is not …
Read More »
Shares of Novavax Inc. NVAX, + 5.66% rally took 2.8% in premier trading Thursday after the biotechnology company said it had concluded a development and supply agreement with South Korea-based SK Group subsidiary SK Bioscience for the antigen component of Novavax’s COVID-19 vaccine candidate, NVX-CoV2373. The companies have also signed …
Read More »
Shares of Seres Therapeutics Inc. MCRB, + 332.15% hit nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapy company reported faster results from a Phase 3 trial of its SER-109 for recurrent C. difficile infections (CDI), as an infection of the colon. Trading volume …
Read More »
Gilead Sciences Inc. GILD, -1.15% announced Tuesday an agreement to purchase a 49.9% stake in private cancer treatment developer Tizona Therapeutics Inc. for $ 300 million. Gilead also received the option to purchase the rest of Tizona for up to an additional $ 1.25 billion, including possible future milestone payments. …
Read More »
Gilead Sciences Inc. GILD, -1.29% announced Tuesday an agreement to purchase a 49.9% stake in private cancer treatment developer Tizona Therapeutics Inc. for $ 300 million. Gilead also received the option to purchase the rest of Tizona for up to an additional $ 1.25 billion, including possible future milestone payments. …
Read More »